SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Higuchi Ichiyō

PatientHiguchi Ichiyō
Date of birth2002-05-02
IdentifiersMRN HR-NI029-SYN; SSN (made up) 000-29-5108
Document date2026-08-24
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. Higuchi is a 24-year-old writer with drug-susceptible pulmonary tuberculosis in the nineteenth week of treatment, now in the continuation phase on isoniazid, rifampin and pyridoxine by video-observed therapy, who comes for the preventive visit booked at her first appointment. Her cough and night sweats have gone, she sleeps well, and she has gained 4 kg since intake. The cystitis five weeks ago settled within two days on nitrofurantoin, and the culture grew Escherichia coli susceptible to it. The sputum culture taken at the end of the intensive phase showed no growth after six weeks. She writes about two hours each morning and has finished a new story. Public funding now covers most of her tuberculosis costs, and the social worker helped her arrange to pay her clinic charges in instalments. She has no new concerns. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 24
TuberculosisWeek 19 of 26; no symptoms; every dose taken
CystitisResolved
MoodPHQ-2 1; GAD-7 4

Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with her by Dr. Lindgren-Tanaka. [S]

DomainFinding
Self-rated healthGood and improving
PsychosocialMoney is her main stress; less worried now that treatment costs are covered; feels supported by her editors and readers
Substance useAUDIT-C 0; no drug use
TobaccoNever smoked; no one smokes at home
Physical activityWalks to the market and back most days, about 30 minutes
NutritionThree meals and two snacks a day with two supplement drinks; more fish, eggs and tofu since the dietitian visits
SleepSeven hours; writing moved from night to morning
SafetyFeels safe at home; intimate partner violence screen negative; smoke alarm at home
Sexual and reproductive healthNot sexually active; not planning a pregnancy; regular periods
Activities of daily livingIndependent

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, night sweats or weight loss; weight rising
EyesNegativeNo change in vision or color vision
Ears, nose, mouth, and throatNegativeNo sore throat or hearing change
CardiovascularNegativeNo chest pain or palpitations
RespiratoryNegativeNo cough, sputum or breathlessness
GastrointestinalNegativeNo nausea, abdominal pain or jaundice
GenitourinaryNegativeNo urinary symptoms since the cystitis; urine orange from rifampin
MusculoskeletalNegativeNo joint pain
IntegumentaryNegativeNo rash
NeurologicalNegativeNo numbness or tingling in the hands or feet
PsychiatricNegativeMood good; PHQ-2 1

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route2026-04-17 to 2026-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route2026-04-17 to 2026-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-04-17 to 2026-10-15completedS
Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five daysOne capsule twice daily with food for five daysOral route2026-07-20 to 2026-07-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-24Body height148cmS
2026-08-24Body weight42.6kgS
2026-08-24Body mass index (BMI) [Ratio]19.4kg/m2S
2026-08-24Systolic blood pressure104mm[Hg]S
2026-08-24Diastolic blood pressure66mm[Hg]S
2026-08-24Heart rate76/minS
2026-08-24Respiratory rate14/minS
2026-08-24Body temperature36.6CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-08-24Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S
2026-08-24Total score [AUDIT-C]0{score}S

Physical Exam

Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]

SystemFinding
ConstitutionalSlim and well; weight 42.6 kg, BMI 19.4; blood pressure 104/66
EyesNo icterus; conjunctivae pink
NeckNo enlarged lymph nodes; thyroid normal
RespiratoryClear on both sides
CardiovascularRegular rhythm; no murmur
AbdomenSoft and non-tender; liver not enlarged
GenitourinarySpeculum examination with a small speculum, with a chaperone and her consent: normal cervix; cytology sample taken
NeurologicalNormal sensation and reflexes in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)activeconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.
Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today104/66 mmHg
Depression screeningCompleted todayPHQ-2 score 1
Anxiety screeningCompleted todayGAD-7 score 4
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 0
Tobacco useCompleted todayNever smoked
Intimate partner violence screeningCompleted todayAsked privately; negative
Cervical cancer screeningCompleted todayCytology at 24, her first screening; every three years from 21 to 29
Chlamydia and gonorrhea screeningNot indicatedNot sexually active; offer when that changes, as for sexually active women 24 or younger
Contraception and pregnancy intentionCompleted todayNot planning a pregnancy; counseled on the rifampin interaction with hormonal methods
Folic acidCompleted todayAdvised 0.4 to 0.8 mg daily, as for anyone who could become pregnant
HIV screeningUp to dateNegative at intake
Hepatitis C screeningUp to dateNegative at intake
Hepatitis B screeningUp to dateAt intake: surface antigen, surface antibody and core antibody negative; not immune
Diabetes screeningUp to dateHemoglobin A1c 5.1% at intake, checked because diabetes worsens tuberculosis outcomes
Tetanus, diphtheria, and pertussisCompleted todayTdap; no adult booster recorded
Hepatitis B vaccineCompleted todayDose 1 of 2 today; dose 2 in eight weeks
HPV vaccineCompleted todayCatch-up dose 1 of 3 today, through age 26
Influenza vaccineDueIn the autumn, at the end-of-treatment visit
COVID-19 vaccineDueDiscuss in the autumn

Immunizations given today: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap); Hepatitis B vaccine (HepB-CpG), dose 1 of 2; Human papillomavirus 9-valent vaccine, dose 1 of 3 [S]

Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); Adult Immunization Schedule by Age (2026)

Follow-up: End-of-treatment visit after the 182nd dose, with the chest X-ray, blood tests, the second hepatitis B and HPV doses and the influenza vaccine. Cytology result by phone. Next preventive visit in one year. Next scheduled visit 2026-10-20: end-of-treatment review after 182 doses. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 16 minutes, with her consent. She understands that her tuberculosis is curable and wants full treatment of any illness. She named a health care agent, recorded in the confidential part of the chart and not named here, and chose to record no other preferences today. To be revisited yearly. [S]